Zacks Investment Research downgraded vTv Therapeutics Inc (NASDAQ:VTVT) to Sell in a report released today.
- Updated: October 12, 2016
Zacks Investment Research has downgraded vTv Therapeutics Inc (NASDAQ:VTVT) to Sell in a report released on 10/12/2016.
Previously on 09/26/2016, HC Wainwright reported about vTv Therapeutics Inc (NASDAQ:VTVT) raised the target price from $0.00 to $13.00. At the time, this indicated a possible upside of 0.81%.
Yesterday vTv Therapeutics Inc (NASDAQ:VTVT) traded 1.45% higher at $6.92. The company’s 50-day moving average is $6.46 and its 200-day moving average is $5.91. The last stock close price is up 17.87% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 3,937 shares of the stock were exchanged, down from an average trading volume of 35,674
See Chart Below
vTv Therapeutics Inc has a 52 week low of $4.84 and a 52 week high of $8.22 The company’s market cap is currently $0.
About vTv Therapeutics Inc (NASDAQ:VTVT)
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.